- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03791060
Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)
An Open-label Proof of Concept Study Regarding the Use of Secukinumab (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Necrobiosis lipoidica diabeticorum (NLD) is a rare granulomatous condition of the skin often presenting with papules and eventually atrophic plaques, most commonly on the distal extensor lower extremities, which can be painful and disfiguring. Currently no FDA-approved treatment exists, and no well-established treatment algorithm has been described. Reports on successful therapeutic interventions have generally been small and inconsistent.
Recent literature expanding on the previously poorly understood pathogenesis of NLD has suggested a potential role for IL-17 in the development of this condition. Thus blockade of IL-17 may be a potential therapeutic strategy in patients with NLD. Secukinumab (Cosentyx) is a human monoclonal antibody that targets IL-17a and is FDA approved for the treatment of psoriasis.
This open-label, proof of concept study regarding the use of Secukinumab in patients with NLD may be a first step in elucidating and defining a treatment for this chronic and potentially debilitating condition for which no FDA approved treatment currently exists.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults, age 18 and over
- Previous diagnosis of biopsy-proven NLD
Active NLD lesions, defined as
- clinical signs of inflammation, for example erythematous margins, sensations of itch, pain, dysaesthesia
- lesions increasing in size or appearance of new lesions within the last 3 months
- ulcerations
- Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study related activity is performed.
Exclusion Criteria:
- History of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection as defined by a positive QuantiFERON TB-Gold test at screening.
- Are currently pregnant, breastfeeding, or planning to get pregnant during the study.
- Previous hypersensitivity reaction to secukinumab or to any of the components.
- History of Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis)
- Allergy to Latex
- Currently on any other immunosuppressant systemic medication or within 28 days of baseline visit
- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unwilling to use effective contraception during the study and for 16 weeks after stopping treatment.
- Subjects with a serum creatinine level exceeding 176.8 μmol/L (2.0 mg/dL)
- Screening total WBC count <2,500/μL, or platelets <100,000/μL or neutrophils <1,500/μL or hemoglobin <8.5 g/dL
- Known infection with HIV, hepatitis B or hepatitis C at screening or randomization. Patients who are Hepatitis B Core antibody and/or Hep B Surface Antigen positive will be excluded from this study. Patients who are Hepatitis C ab positive will also be excluded from this study.
- History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years (except for non-melanoma skin cancer and carcinoma in situ of the cervix)
- Are participating in another study using an investigational agent or procedure during participation in this study or within 28 days prior to baseline visit.
- Plans for administration of live vaccines during the study period or 6 weeks prior to randomization
- Any other procedural treatment for NLD with 28 days prior to baseline visit, including phototherapy, surgical intervention, laser therapy, or cryotherapy.
- Any other active skin disease or condition (e.g., bacterial, fungal or viral infection) that may interfere with assessment of NLD;
- Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the investigator significantly immunocompromises the subject and/or places the subject at unacceptable risk for receiving an immunomodulatory therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Secukinumab Subcutaneous Injection
300 mg q weekly for 5 weeks followed by 300 mg q 4 weeks. Each subject will receive 300mg of Secukinumab by using 2 syringes of 150mg each as a subcutaneous injection at weeks 0,1,2,3,4 then every 4 weeks for a total of 9 doses over 24 weeks. |
Secukinumab is selective for human IL-17A and potently neutralizes the bioactivity of this cytokine.
IL-17A is the central cytokine in multiple autoimmune and inflammatory processes.
It is being recognized as one of the principal pro-inflammatory cytokines in autoimmune diseases such as psoriasis, PsA and AS, uveitis and is thought to play a role in other inflammatory conditions.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Investigator Global Assessment Score
Time Frame: 24 weeks
|
Proportion of patients achieving remission or clinical improvement based on Investigator Global Assessment Score as measured at week 24. Score Description 0. Completely clear: except for possible residual hyperpigmentation
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Histology
Time Frame: 26 weeks
|
Proportion of subjects achieving improvement based upon histological score. The score is calculated by adding subscores as listed below, which will be evaluated by the dermatopathologist. Average of pre and post scores and overall change in score will be calculated and compared using a paired T-test.
|
26 weeks
|
Pain Score
Time Frame: Assessed at week 1, 2, 3, 4, 8, 12, 16, 20, 25
|
Self-reported pain and stinging intensity during and directly after treatment with Secukinumab injections A Pain Score will be calculated based upon the Wong-Baker 10-point pain score, which has been widely used to rate pain in both children and adults and has also been used in dermatology clinical trials. Response based on an improvement from baseline in the Wong-Baker pain score at all scheduled time points will be calculated. We will compare pre and post treatment pain values and categorize patients as (i) Resolved (ii) Improved (iii) Stable (iv) Worsened |
Assessed at week 1, 2, 3, 4, 8, 12, 16, 20, 25
|
Dermatology Life Quality Index
Time Frame: Assessed at week 1, 2, 3, 4, 8, 12, 16, 20, 25
|
Proportion of subjects improving based upon patient-reported outcomes The DLQI is a validated general dermatology questionnaire that consists of 10 items that assess subject health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment) The DLQI is a psychometrically valid and reliable instrument that has been translated into several languages, and the DLQI total scores have been shown to be responsive to change.
The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
|
Assessed at week 1, 2, 3, 4, 8, 12, 16, 20, 25
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Alexa Kimball, MD MPH, Beth Israel Deaconess Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018P000634
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Necrobiosis Lipoidica Diabeticorum
-
Aaron R. MangoldCompletedNecrobiosis LipoidicaUnited States
-
Processa PharmaceuticalsCompletedA Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis LipoidicaNecrobiosis LipoidicaUnited States
-
Processa PharmaceuticalsTerminatedNecrobiosis LipoidicaUnited States
Clinical Trials on Secukinumab
-
Novartis PharmaceuticalsRecruiting
-
Technical University of MunichNovartisCompletedPyoderma GangrenosumGermany
-
Novartis PharmaceuticalsCompletedPlaque PsoriasisThailand
-
Novartis PharmaceuticalsCompletedPlaque PsoriasisUnited States
-
University of Erlangen-Nürnberg Medical SchoolActive, not recruiting
-
Novartis PharmaceuticalsCompletedPsoriatic Arthritis | Axial SpondyloarthritisSpain
-
Novartis PharmaceuticalsCompletedPsoriasisUnited States
-
Saakshi KhattriCompleted
-
Novartis PharmaceuticalsTerminatedLupus NephritisChina, Croatia, Czechia, Russian Federation, Turkey, Australia, Spain, Thailand, Argentina, United States, Denmark, Greece, Romania, Germany, Korea, Republic of, India, Brazil, Japan, Peru, Portugal, Italy, Taiwan, Vietnam, Norway, Colo... and more